Kumar S, Harrison S, Cavo M, et al. A phase 3 study of venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. 24th Congress of EHA, abstract LB2601.
DHC 2022: ‘Optimale fludarabine-waarde kan doel worden bij CAR-T-celtherapie’
mrt 2022 | Leukemie